Key clinical point: Lenzilumab, a GM-CSF-targeted monoclonal antibody, reduced chimeric antigen receptor (CAR) T-cell toxicity and may have potentiated its antitumor effects in early investigations.
Major finding: Lenzilumab reduced neurotoxicity and cytokine release syndrome related to CD19-targeted CAR T-cell therapy in a patient-derived xenograft model.
Study details: A series of in vitro and in vivo studies looking at the effects of lenzilumab in cell lines and animal models.
Disclosures: Ms. Sterner reported that she had no financial disclosures related to her presentation.
Sterner R et al. TCT 2019, Abstract 5.